Press releases – Oncopeptides

Oncopeptides Welcomes New Board Member – Luigi Costa

August 15, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing an effective, peptidase targeted therapy for the treatment of multiple myeloma announces the appointment of Luigi Costa to its Board of Directors.

Oncopeptides Present Phase 2 Clinical Data at the European Hematology Association in Copenhagen, Denmark, June 2016

July 7, 2016 - Other press release

Oncopeptides AB, a clinical stage company developing the peptidase targeted therapy – melflufen – announced that clinical results from a Phase 2 study of melflufen and dexamethasone in patients with rel...

Oncopeptides prepare for pivotal Phase 3 clinical trials

April 30, 2016 - Other press release

Oncopeptides have had a number of interactions with the regulatory authorities over the last months, and as a result the company will make preparations to be ready to begin pivotal Phase 3 clinical trials...

Oncopeptides have a successful meeting with MHRA

March 31, 2016 - Other press release

Oncopeptides had a successful meeting with MHRA on March 23rd to discuss the design of the upcoming pivotal trial of melflufen in late-stage relapsed and refractory multiple myeloma patients.

Oncopeptides CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.

January 13, 2016 - Other press release

Oncopeptides and CEO Jakob Lindberg featured in the latest Monocl blog about multiple myeloma.